Biotech, Partnering

Editas scoops CRISPR/Cas9 and TALE genome editing technologies from 4 academics groups

Posted on 02 December 2014

Tags: , ,

Editas Medicine have entered into a series of license agreements to access intellectual property and technology related to the CRISPR/Cas9 and TALENs genome editing systems, as follows:

  • Massachusetts General Hospital to access intellectual property and technology related to the CRISPR/Cas9 and TALENs genome editing systems. The license allows broad utilization of the technology developed in the laboratory of Editas founder, J. Keith Joung, M.D., Ph.D., for the prevention and treatment of human or animal disease, and broad agricultural use
  • Duke University to access intellectual property and technology related to the CRISPR/Cas9 and TALEN genome editing systems. The license allows broad utilization of the technology developed in the laboratory of Charles Gersbach, Ph.D., for the prevention or treatment of human disease
  • Broad Institute of MIT and Harvard and Harvard University to access intellectual property and technology related to the CRISPR/Cas9 and TALE genome editing systems. The license allows broad utilization of the technology developed by Editas founders, Feng Zhang, Ph.D., of the Broad Institute, and George Church, Ph.D., and David R. Liu, Ph.D., both of Harvard University, for the prevention and treatment of human disease

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

 

Print Friendly, PDF & Email

Leave a Reply